Residency · Residency · Critical Care

Acute Kidney Injury in the ICU

Definitions and Staging

KDIGO Criteria (2012)

The Kidney Disease: Improving Global Outcomes classification system defines and stages acute kidney injury based on changes in serum creatinine and urine output. Stage 1 is defined by a creatinine rise of 0.3 mg/dL or greater within 48 hours, or a rise to 1.5 to 1.9 times baseline within 7 days, or a urine output below 0.5 mL/kg/hr for 6 to 12 hours. Stage 2 requires a creatinine rise to 2.0 to 2.9 times baseline or urine output below 0.5 mL/kg/hr for 12 hours or more. Stage 3 is defined by a creatinine rise to 3.0 times baseline or greater, or an absolute creatinine of 4.0 mg/dL or greater, or initiation of renal replacement therapy, or urine output below 0.3 mL/kg/hr for 24 hours or more, or anuria for 12 hours or more. The limitations of creatinine as a biomarker must be recognized: it is a delayed indicator, rising 24 to 48 hours after injury has occurred, and its levels are affected by muscle mass, fluid balance, and catabolic state, all of which fluctuate dramatically in critically ill patients.

Epidemiology in ICU

Acute kidney injury is remarkably prevalent in the ICU, affecting 50 to 60 percent of patients, with 5 to 10 percent requiring renal replacement therapy. Even Stage 1 AKI independently increases hospital mortality by 2 to 3 times, establishing it as one of the most consequential organ dysfunctions in critical illness. Sepsis is the most common cause, accounting for 40 to 50 percent of ICU-AKI. The long-term consequences extend far beyond the acute hospitalization: 25 to 30 percent of patients with severe AKI develop chronic kidney disease within 1 to 3 years, and ICU survivors with AKI face a 10-fold increased risk of end-stage kidney disease.

Pathophysiology

Pre-Renal AKI (Functional)

Pre-renal AKI results from reduced renal perfusion without structural parenchymal injury. The causes include hypovolemia, cardiogenic shock, hepatorenal syndrome, and bilateral renal artery stenosis. Diagnostic markers include a fractional excretion of sodium below 1 percent, a fractional excretion of urea below 35 percent, and a BUN-to-creatinine ratio above 20:1. The hallmark of pre-renal AKI is its reversibility: creatinine normalizes within 24 to 48 hours of restoring adequate perfusion. However, prolonged pre-renal conditions transition to acute tubular necrosis as functional ischemia progresses to structural injury.

Intrinsic AKI

Acute tubular necrosis is the most common form of intrinsic AKI in the ICU and occurs through ischemic or nephrotoxic mechanisms. Ischemic ATN results from prolonged hypoperfusion causing tubular cell injury and necrosis, producing the characteristic muddy brown granular casts on urine microscopy. Nephrotoxic ATN is caused by aminoglycosides, contrast media, myoglobin from rhabdomyolysis, and uric acid from tumor lysis syndrome. Septic AKI deserves particular emphasis because it is not a purely pre-renal phenomenon, as was historically taught. Current understanding recognizes that septic AKI involves microcirculatory dysfunction with shunting at the cortical level, direct inflammatory injury to tubular cells, and mitochondrial metabolic reprogramming, even in the presence of normal or increased total renal blood flow.

Acute interstitial nephritis represents a drug-induced allergic reaction to beta-lactam antibiotics, proton pump inhibitors, or NSAIDs, among other agents. Urine eosinophils have disappointing sensitivity of only 30 to 40 percent, and definitive diagnosis often requires renal biopsy. Rapidly progressive glomerulonephritis from ANCA-associated vasculitis, anti-GBM disease, or lupus nephritis requires urgent diagnosis and treatment. Vascular causes include renal artery thrombosis, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, cholesterol embolization, and renal cortical necrosis.

Post-Renal AKI (Obstructive)

Post-renal AKI from bilateral ureteral obstruction or bladder outlet obstruction should be excluded in every case of AKI because it is immediately reversible. Causes include nephrolithiasis, malignancy, retroperitoneal fibrosis, and benign prostatic hyperplasia, the last being the most common cause of bladder outlet obstruction. Diagnosis is made by renal ultrasound demonstrating hydronephrosis or by demonstrating significant post-void residual with Foley catheter placement.

<image>Comprehensive AKI pathophysiology diagram showing three columns for pre-renal, intrinsic, and post-renal causes. Pre-renal column: reduced renal blood flow with afferent arteriole, showing diminished perfusion from dehydration/shock/HRS, with autoregulatory response (afferent dilation, efferent constriction). Intrinsic column subdivided into four compartments: tubular (ATN — showing proximal tubular cell injury with loss of brush border, cell sloughing, cast formation in lumen), interstitial (AIN — inflammatory infiltrate with eosinophils), glomerular (crescentic GN with disrupted Bowman's capsule), and vascular (thrombotic microangiopathy with fibrin strands and fragmented RBCs). Post-renal column: obstructed ureter with proximal hydronephrosis. Below each column: diagnostic markers (FENa, urine microscopy findings, imaging).</image>

Diagnostic Approach

Urine Studies

Urinalysis provides initial screening information including specific gravity, protein, blood, and leukocyte esterase. Urine microscopy is an essential but underutilized diagnostic tool in ICU-AKI. Muddy brown granular casts are highly sensitive and specific for acute tubular necrosis. Red blood cell casts indicate glomerulonephritis. White blood cell casts suggest pyelonephritis or acute interstitial nephritis. Fractional excretion of sodium below 1 percent suggests pre-renal physiology while values above 2 percent suggest ATN, though this test becomes unreliable after diuretic administration, at which point fractional excretion of urea should be used, with values below 35 percent indicating pre-renal and above 50 percent indicating ATN. Urine sodium below 20 mEq/L in oliguric patients supports a pre-renal etiology while values above 40 mEq/L suggest ATN.

Novel Biomarkers

Novel biomarkers offer the potential for earlier AKI detection. NGAL rises 2 to 6 hours after tubular injury, well before creatinine elevation. KIM-1 is a proximal tubular injury marker. The cell cycle arrest markers TIMP-2 and IGFBP7, marketed as NephroCheck, are FDA-approved for AKI risk prediction, with a product above 0.3 indicating moderate risk and above 2.0 indicating high risk for developing stage 2 or 3 AKI within 12 hours. While not yet standard of care, these biomarkers are emerging as tools for identifying high-risk patients who may benefit from early preventive interventions through the KDIGO care bundle.

Imaging

Renal ultrasound should be performed to exclude obstruction and assess kidney size, with small bilateral kidneys suggesting pre-existing CKD and normal or enlarged kidneys indicating an acute process. Doppler ultrasound measuring the renal resistive index, with values above 0.70 suggesting intrinsic parenchymal disease or elevated renal venous pressure, provides additional information. CT angiography is indicated when vascular occlusion is suspected. Renal biopsy should be considered when the etiology remains unclear and the diagnosis will change management, particularly when glomerulonephritis, acute interstitial nephritis, or thrombotic microangiopathy is suspected.

Prevention

KDIGO AKI Bundle

The KDIGO AKI prevention bundle encompasses discontinuation of all nephrotoxic agents when possible, including NSAIDs, aminoglycosides, and radiocontrast; ensuring adequate volume status and perfusion pressure while avoiding both hypovolemia and fluid overload; considering functional hemodynamic monitoring to guide fluid therapy; avoiding hyperglycemia with glucose targets below 180 mg/dL while preventing hypoglycemia; close monitoring of serum creatinine and urine output; and considering alternatives to radiocontrast when feasible.

Contrast-Induced AKI (CI-AKI)

The risk of contrast-induced AKI is determined by pre-existing CKD with eGFR below 30, diabetes, heart failure, and high-volume contrast administration. The only proven preventive measure is intravenous isotonic saline hydration at 1 mL/kg/hr for 12 hours before and after contrast administration. The PRESERVE trial of 2018 definitively demonstrated that N-acetylcysteine provides no benefit in preventing contrast-induced AKI. The AMACING trial suggested that hydration may not be necessary when eGFR is above 30.

Nephrotoxin Stewardship

Aminoglycoside nephrotoxicity is minimized through extended-interval dosing every 24 to 48 hours with trough-based or AUC-based monitoring. Vancomycin dosing has shifted toward AUC/MIC targeting of 400 to 600, with AUC-guided dosing preferred over trough-based approaches. Liposomal amphotericin B formulations substantially reduce nephrotoxicity compared to conventional preparations. NSAIDs should be avoided in critical illness, as their inhibition of prostaglandin-mediated afferent arteriolar vasodilation impairs renal autoregulation.

Management of Established AKI

Supportive Care

Fluid management requires balancing the avoidance of hypovolemia against the prevention of fluid overload, which at levels exceeding 10 percent of body weight is independently associated with mortality in AKI. Active fluid removal through diuresis or ultrafiltration should be pursued once hemodynamic stability is achieved. Hemodynamic optimization targets a MAP of 65 mmHg or greater, as the SEPSISPAM trial demonstrated that higher MAP targets of 80 mmHg do not improve renal outcomes in sepsis except possibly in patients with pre-existing chronic hypertension. Nephrotoxic agents must be discontinued and drug doses adjusted for reduced GFR. Nutrition should maintain standard ICU targets with protein delivery of 1.2 to 2.0 g/kg/day for patients on CRRT, as protein should not be restricted to delay dialysis.

Drug Dosing in AKI

Drug dosing in AKI is complicated by the phenomenon of augmented renal clearance that can occur in early sepsis, producing increased rather than decreased drug clearance and creating the risk of subtherapeutic dosing. Vancomycin and aminoglycoside doses must be adjusted based on drug levels. Hydrophilic antibiotics including beta-lactams have reduced clearance in AKI, requiring dose reduction or extended infusion strategies. CRRT significantly alters drug clearance in ways that are difficult to predict, necessitating pharmacy consultation and the use of CRRT-specific dosing guidelines. Loading doses should be reconsidered, as the volume of distribution changes with fluid overload and CRRT.

Diuretics in AKI

The furosemide stress test provides the best bedside prediction of AKI progression and the need for renal replacement therapy. After administration of a furosemide bolus of 1 mg/kg in diuretic-naive patients or 1.5 mg/kg in patients with prior diuretic exposure, a urine output below 200 mL in 2 hours predicts progression to Stage 3 AKI and need for RRT with a sensitivity of 87 percent and specificity of 84 percent. Diuretics do not prevent AKI or reduce mortality and should be used only for volume management. Conversion to continuous furosemide infusion at 5 to 40 mg/hr is appropriate for persistent fluid overload.

Electrolyte Management

Hyperkalemia is the most dangerous complication of AKI, with potassium above 6.0 mEq/L or ECG changes necessitating emergent treatment. The management cascade includes calcium gluconate at 1 to 3 grams intravenously for membrane stabilization, regular insulin at 10 units with D50W for intracellular potassium shift, sodium bicarbonate at 50 to 150 mEq if the patient is acidotic, nebulized albuterol at 10 to 20 mg for additional intracellular shift, and potassium-binding agents including the newer sodium zirconium cyclosilicate which has a faster onset than older agents. Emergent dialysis is required for refractory hyperkalemia. The BICAR-ICU trial demonstrated that sodium bicarbonate therapy in severe metabolic acidemia with pH below 7.15 reduced 28-day mortality in the AKI subgroup at 46 versus 63 percent. Hyperphosphatemia is managed with phosphate binders, dietary restriction, and dialysis. Hypocalcemia should be corrected only when symptomatic or before dialysis.

<image>Furosemide stress test protocol and interpretation algorithm. Starting box: "AKI Stage 1-2, considering RRT timing." Step 1: assess volume status (euvolemic or hypervolemic). Step 2: administer furosemide IV bolus (1 mg/kg if diuretic-naive, 1.5 mg/kg if on prior diuretics). Step 3: collect urine for 2 hours with strict measurement. Outcome branch: UOP >=200 mL in 2 hours → low risk of progression (continue monitoring, repeat FST daily); UOP <200 mL in 2 hours → high risk of Stage 3 AKI and RRT need (initiate RRT planning, discuss goals of care, consider early dialysis access). Include sensitivity/specificity data, and note that FST replaces lost fluid with isotonic crystalloid to maintain euvolemia during test.</image>

Specific AKI Syndromes in ICU

Sepsis-Associated AKI

Sepsis-associated AKI is the most common cause of AKI in the ICU at 40 to 50 percent. The pathophysiology challenges the traditional pre-renal paradigm, as renal blood flow may be normal or even increased during septic AKI. The injury is driven by microcirculatory dysfunction with cortical shunting, direct inflammatory injury to tubular epithelium, and mitochondrial reprogramming. Management centers on treating sepsis, maintaining adequate perfusion pressure, and avoiding nephrotoxins. The recovery pattern is often non-oliguric initially, with a polyuric phase during recovery.

Rhabdomyolysis

Rhabdomyolysis with a CK above 5,000 U/L carries AKI risk that increases significantly when CK exceeds 15,000 to 20,000 U/L. The mechanisms include myoglobin cast nephropathy, tubular obstruction, direct tubular toxicity from free iron, and renal vasoconstriction. Treatment requires aggressive crystalloid resuscitation targeting urine output of 200 to 300 mL/hr. Sodium bicarbonate alkalinization of urine to a pH above 6.5 may theoretically prevent myoglobin precipitation, though direct evidence is limited. Mannitol has no proven benefit and may worsen volume depletion. Calcium supplementation should be avoided unless symptomatic, as rebound hypercalcemia commonly occurs during recovery.

Hepatorenal Syndrome (HRS)

Type 1 hepatorenal syndrome, now termed HRS-AKI, manifests as rapid creatinine doubling within 2 weeks and carries a very poor prognosis. It is a diagnosis of exclusion requiring elimination of other AKI causes and demonstrating no improvement after a volume challenge with albumin at 1 g/kg/day for 2 days. Treatment with terlipressin plus albumin was validated by the CONFIRM trial of 2022, which demonstrated improved HRS reversal at 32 versus 17 percent and led to FDA approval. Alternatives include norepinephrine plus albumin or the combination of midodrine, octreotide, and albumin. Definitive treatment is liver transplantation.

Abdominal Compartment Syndrome

Abdominal compartment syndrome is defined by an intra-abdominal pressure above 20 mmHg with new organ dysfunction and is measured via intravesicular bladder pressure, with normal values below 12 mmHg. The elevated intra-abdominal pressure reduces renal perfusion by compressing renal parenchyma and renal veins. Management includes decompressive laparotomy, percutaneous drainage, and neuromuscular blockade.

Key Clinical Pearls

• Creatinine is a delayed AKI biomarker — rises 24-48 hours after injury; urine output changes are often earlier
• FENa and urine sodium are unreliable after diuretic administration — use FEUrea instead
• The furosemide stress test (UOP <200 mL in 2 hours after 1-1.5 mg/kg bolus) is the best bedside predictor of AKI progression and RRT need
• Septic AKI is not purely a pre-renal phenomenon — renal blood flow may be normal or increased; microcirculatory dysfunction and inflammation drive injury
• Fluid overload >10% of body weight is independently associated with mortality — active fluid removal should be pursued once hemodynamically stable
• NAC does not prevent contrast-induced AKI (PRESERVE trial) — hydration with isotonic saline remains the only proven preventive measure
• BICAR-ICU trial: sodium bicarbonate may reduce mortality in severe metabolic acidosis with AKI (pH <7.20)
• All ICU patients with AKI should be followed post-discharge for CKD development — 25-30% develop CKD within 1-3 years

References

1. Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary. Crit Care. 2013;17(1):204.
2. Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU). Lancet. 2018;392(10141):31-40.
3. Koyner JL, Davison DL, Brasha-Mitchell E, et al. Furosemide stress test and biomarkers for the prediction of AKI severity. J Am Soc Nephrol. 2015;26(8):2023-2031.
4. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med. 2018;378(7):603-614.
5. Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818-828.

Read this lecture as Markdown